Literature DB >> 23117977

The COPD control panel: towards personalised medicine in COPD.

Alvar Agusti1, William MacNee.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease whose assessment and management have traditionally been based on the severity of airflow limitation (forced expiratory volume in 1 s (FEV1)). Yet, it is now clear that FEV1 alone cannot describe the complexity of the disease. In fact, the recently released Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011 revision has proposed a new combined assessment method using three variables (symptoms, airflow limitation and exacerbations).
METHODS: Here, we go one step further and propose that in the near future physicians will need a 'control panel' for the assessment and optimal management of individual patients with complex diseases, including COPD, that provides a path towards personalised medicine.
RESULTS: We propose that such a 'COPD control panel' should include at least three different domains of the disease: severity, activity and impact. Each of these domains presents information on different 'elements' of the disease with potential prognostic value and/or with specific therapeutic requirements. All this information can be easily incorporated into an 'app' for daily use in clinical practice.
CONCLUSION: We recognise that this preliminary proposal needs debate, validation and evolution (eg, including 'omics' and molecular imaging information in the future), but we hope that it may stimulate debate and research in the field.

Entities:  

Keywords:  COPD Exacerbations; COPD Pharmacology; COPD epidemiology

Mesh:

Year:  2012        PMID: 23117977     DOI: 10.1136/thoraxjnl-2012-202772

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Authors:  Alvar Agustí; Josep Maria Antó; Charles Auffray; Ferran Barbé; Esther Barreiro; Jordi Dorca; Joan Escarrabill; Rosa Faner; Laura I Furlong; Judith Garcia-Aymerich; Joaquim Gea; Bertil Lindmark; Eduard Monsó; Vicente Plaza; Milo A Puhan; Josep Roca; Juan Ruiz-Manzano; Laura Sampietro-Colom; Ferran Sanz; Luis Serrano; James Sharpe; Oriol Sibila; Edwin K Silverman; Peter J Sterk; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [(18)F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation.

Authors:  Nathalie Matusiak; Aren van Waarde; Dennie Rozeveld; Antoon J M van Oosterhout; Irene H Heijink; Riccardo Castelli; Herman S Overkleeft; Rainer Bischoff; Rudi A J O Dierckx; Philip H Elsinga
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

3.  Fibrinogen and COPD: Now what?

Authors:  Rosa Faner; Alvar Agusti
Journal:  Chronic Obstr Pulm Dis       Date:  2015-01-24

4.  Chronic obstructive pulmonary disease at the beginning of the XXI Century.

Authors:  Alvar Agusti; Jing Zhang
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

Review 5.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

6.  Bronchodilator Response in Patients with COPD, Asthma-COPD-Overlap (ACO) and Asthma, Evaluated by Plethysmographic and Spirometric z-Score Target Parameters.

Authors:  Richard Kraemer; Hans-Jürgen Smith; Fabian Gardin; Jürg Barandun; Stefan Minder; Lukas Kern; Martin H Brutsche
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-01

7.  2012 highlights in translational 'omics.

Authors:  Charles Auffray; Timothy Caulfield; Muin J Khoury; James R Lupski; Matthias Schwab; Timothy Veenstra
Journal:  Genome Med       Date:  2013-01-31       Impact factor: 11.117

Review 8.  Pulmonary function testing in COPD: looking beyond the curtain of FEV1.

Authors:  Sotirios Kakavas; Ourania S Kotsiou; Fotis Perlikos; Maria Mermiri; Georgios Mavrovounis; Konstantinos Gourgoulianis; Ioannis Pantazopoulos
Journal:  NPJ Prim Care Respir Med       Date:  2021-05-07       Impact factor: 2.871

9.  Impact of a patient-specific co-designed COPD care scorecard on COPD care quality: a quasi-experimental study.

Authors:  C Michael Roberts; Gulsen Gungor; Mike Parker; John Craig; James Mountford
Journal:  NPJ Prim Care Respir Med       Date:  2015-03-26       Impact factor: 2.871

10.  Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD.

Authors:  Annerika H M Slok; Johannes C C M in 't Veen; Niels H Chavannes; Thys van der Molen; Maureen P M H Rutten-van Mölken; Huib A M Kerstjens; Philippe L Salomé; Sebastiaan Holverda; P N Richard Dekhuijzen; Denise Schuiten; Guus M Asijee; Onno C P van Schayck
Journal:  NPJ Prim Care Respir Med       Date:  2014-07-10       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.